LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with DestiNA Genomics, a manufacturer of patented reagents for nucleic acid detection. Both companies are pioneering microRNA detection and this collaboration brings together high-specificity and ultra-sensitivity for the first time, enhancing RNA biomarker detection. The collaboration’s initial efforts are focusing on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122, which is shown to have earlier and more specific performance than current protein biomarker assays.
“We are very excited to work with DestiNA’s chemistry, which enables the direct and specific detection of microRNAs without the need for sample purification or amplification. Running these assays on the Simoa platform provides the highest level of non-PCR sensitivity for nucleic acid detection, and can greatly simplify a wide range of nucleic acid-based tests,” said Kevin Hrusovsky, CEO, President and Chairman, Quanterix. “Not only is Simoa the most sensitive technology for protein biomarkers – but our work with DestiNA is showing the potential of Simoa to transform DNA and RNA biomarker analysis.”
DestiNA’s breakthrough proprietary ‘Stabiltech’ buffer allows the direct quantification of microRNAs to single base resolution without isolation from serum or plasma. This proprietary capability also enables the shipment and storage of samples prior to analysis at room temperatures, eliminating the need for refrigeration, promising better work flows and more reliable results.
The combination of Quanterix’ SR-X Ultra-Sensitive Biomarker Detection System™ and DestiNA’s proprietary chemistry gives researchers access to a PCR-free approach that delivers a simpler, faster preparation and analysis time, as well as high accuracy. The ability to detect microRNA from serum and plasma without PCR creates significant opportunities for the development of microRNA as valuable clinical biomarkers, particularly in the pharmaceutical, animal health and crop protection sectors.
DestiNA has also purchased the SR-X for its Research and Development Center in the Science Park of Granada, Spain, and is poised to become the first company in Europe to offer novel circulating RNA-based assays. Among new assays planned are those based on detection of exosomal RNA such as ALK variants, and a range of simplified, robust RNA-based assays.
“We are thrilled to partner with Quanterix, and believe this collaboration demonstrates a significant momentum in RNA detection,” said Hugh Ilyine, CEO, DestiNA Genomics. “The combination of our proprietary chemistry with Quanterix’ ultra-sensitive Simoa technology has the potential to unlock significant oportunities in nucleic acid testing.”
Quanterix will be offering the microRNA-122 assay in its Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development and sample testing.
To learn more about the SR-X Ultra-Sensitive Biomarker Detection System™ and its nucleic acid detection capabilities, please visit: https://www.quanterix.com/srx.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
About DestiNA Genomics
DestiNA Genomics is a developer of novel reagents for PCR free, direct detection of microRNAs. Its unique proprietary chemistry enables rapid, reliable detection and quantification of microRNAs from body fluids. Combining DestiNA’s ‘Stabiltech’ buffer and reagents with the ultra-sensitive Quanterix Simoa HD-1 and SR-X platforms delivers refrigeration free, direct detection of microRNAs. DestiNA is now working with pharmaceutical companies supporting their drug development with its microRA-122 assay, as well servicing novel microRNAs biomarker assay projects for academic and industry research, covering cancer and diseases. The company was established in 2010, and is based in Scotland and Spain. Its aim is to transform detection of microRNAs for research and clinical diagnostic uses. For additional information, visit http://destinagenomics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.